STOCK TITAN

Apellis Pharmace - APLS STOCK NEWS

Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.

Apellis Pharmaceuticals, Inc. (APLS) is a leader in developing transformative therapies targeting the complement system, with approved treatments for geographic atrophy and rare blood disorders. This page provides investors and researchers with essential updates on the company’s progress in retinal, hematologic, and renal disease innovation.

Access timely announcements including FDA decisions, clinical trial results, and strategic partnerships that demonstrate Apellis’ commitment to advancing complement immunotherapy. Our curated news collection covers critical developments such as SYFOVRE’s commercial adoption, EMPAVELI’s clinical applications, and research collaborations expanding therapeutic pipelines.

Key updates include regulatory milestones in ophthalmology, hematology treatment expansions, and nephrology research advancements. Bookmark this page to stay informed about Apellis’ pioneering work in C3-targeted therapies and its impact on addressing diseases with limited treatment options.

Rhea-AI Summary

Apellis Pharmaceuticals (APLS) announced that the FDA accepted its New Drug Application (NDA) for pegcetacoplan, targeting paroxysmal nocturnal hemoglobinuria (PNH), and granted Priority Review. The PDUFA action date is set for May 14, 2021. The FDA will not hold an advisory committee meeting to discuss the application. Pegcetacoplan showed superiority over eculizumab in the Phase 3 PEGASUS study, enhancing hemoglobin levels significantly. Apellis plans to initiate an early access program in the U.S. for patients with ongoing disease activity despite C5 inhibition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Summary

Apellis Pharmaceuticals (APLS) announced findings from a major retrospective study on geographic atrophy (GA) secondary to age-related macular degeneration (AMD), presented at the AAO 2020. Involving over 69,000 patients, the data reveal significant disease progression, with up to 21.6% of bilateral GA patients developing new-onset wet AMD in 24 months. The study emphasizes the pressing need for effective treatment for GA, which affects five million people globally. Currently, there are no approved therapies for GA, although Apellis is advancing pegcetacoplan in Phase 3 studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
-
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in two key investor conferences this November. The company will present at the Stifel 2020 Virtual Healthcare Conference on November 18 at 10:00 a.m. ET and at the Jefferies Virtual London Healthcare Conference on November 19 at 6:45 a.m. ET. CEO Cedric Francois will partake in a fireside chat and a podium presentation, respectively. Both events will be webcast live and available for replay for 90 days. Apellis focuses on developing innovative therapies for diseases involving the complement cascade.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
conferences
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced that eight abstracts highlighting the efficacy of pegcetacoplan for treating paroxysmal nocturnal hemoglobinuria (PNH) have been accepted for the virtual American Society of Hematology Annual Meeting from December 5-8, 2020. New analyses from the Phase 3 PEGASUS study show superior treatment response and quality-of-life improvements with pegcetacoplan compared to eculizumab. The matching-adjusted indirect comparison indicated notable enhancements in clinical outcomes when compared to ravulizumab, demonstrating pegcetacoplan's potential to redefine PNH care standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences
-
Rhea-AI Summary

Apellis Pharmaceuticals announces a collaboration with Sobi for the co-development and ex-U.S. commercialization of systemic pegcetacoplan, potentially worth $1.25 billion. The EMA validated the marketing authorization application for pegcetacoplan in PNH. Key trial results include a 52% reduction in lesion growth in geographic atrophy patients and a 73.3% reduction in proteinuria in C3G patients. As of September 30, 2020, Apellis has $728.2 million in cash, supporting operations through 2022 despite a net loss of $135.7 million in Q3 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
-
Rhea-AI Summary

Apellis Pharmaceuticals and Sobi have entered a strategic collaboration for the global co-development and exclusive ex-U.S. commercialization of systemic pegcetacoplan, a targeted C3 therapy. Apellis retains U.S. rights and global rights for ophthalmological pegcetacoplan. Sobi will pay an upfront fee of $250 million, with up to $915 million in milestones and royalties. The partnership aims to advance systemic pegcetacoplan in five registrational programs, targeting diseases in hematology, nephrology, and neurology, with pivotal studies slated to begin in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none
Rhea-AI Summary

Apellis Pharmaceuticals (APLS) has released 18-month data from the Phase 1b APL2-103 study, demonstrating that intravitreal pegcetacoplan effectively slows the growth of geographic atrophy (GA) lesions. The post hoc analysis of seven patients exhibited a 52% reduction in lesion growth in the treated eye compared to the untreated eye. With no reported inflammation and only one case of new-onset exudation, the results indicate the safety of pegcetacoplan. Top-line data from the ongoing Phase 3 DERBY and OAKS studies are expected in Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
-
Rhea-AI Summary

Apellis Pharmaceuticals (APLS) announced results from a 41-patient observational study showing that elevated systemic levels of C3a correlate with COVID-19 severity. In a Phase 1/2 interventional study, initial safety results from six patients indicate APL-9, a targeted C3 therapy, may improve outcomes in severe cases. Key findings include that 97.5% of patients had significantly high C3a levels, averaging 3.7 times the upper limit of normal. An independent committee recommended continuing the investigation of APL-9, which is currently enrolling 60 more patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
covid-19
-
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced positive results from the Phase 2 DISCOVERY study on pegcetacoplan for C3 glomerulopathy (C3G). Patients exhibited a mean reduction of over 65% in proteinuria after 48 weeks, a key indicator of kidney damage. The study included eight C3G patients, where one showed a 73.3% decrease in proteinuria, alongside improvements in serum albumin and renal function. No severe adverse events were recorded, demonstrating the treatment's potential for this rare disease without approved therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.92%
Tags
conferences clinical trial
Rhea-AI Summary

Apellis Pharmaceuticals has granted equity awards to four new employees as an inducement to join the company. The awards, totaling options for 25,962 shares and 4,275 restricted stock units (RSUs), were approved under the 2020 Inducement Stock Incentive Plan. The options have an exercise price of $31.77, equal to the stock's closing price on the grant date, October 1, 2020. Vesting for options occurs yearly after the first year, while RSUs vest at 25% annually. This initiative aims to enhance workforce engagement and retention.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Apellis Pharmace

Nasdaq:APLS

APLS Rankings

APLS Stock Data

2.28B
107.71M
13.86%
103.5%
16.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM